BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 4827071)

  • 1. Identification of susceptibility to malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1974 May; 2(5913):245-7. PubMed ID: 4827071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical basis of malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1974 May; 2(5913):241-4. PubMed ID: 4827070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for malignant hyperpyrexia.
    Ellis FR; Keaney NP; Harriman DG; Sumner DW; Kyei-Mensah K; Tyrrell JH; Hargreaves JB; Parikh RK; Mulrooney PL
    Br Med J; 1972 Sep; 3(5826):559-61. PubMed ID: 5069639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
    Ording H; Skovgaard LT
    Acta Anaesthesiol Scand; 1987 Jul; 31(5):462-5. PubMed ID: 3630591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of susceptibility to malignant hyperpyrexia in swine.
    Okumura F; Crocker BD; Denborough MA
    Br J Anaesth; 1979 Mar; 51(3):171-6. PubMed ID: 435338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temperature dependence of muscle function in malignant hyperpyrexia-susceptible swine.
    Sullivan JS; Denborough MA
    Br J Anaesth; 1981 Nov; 53(11):1217-22. PubMed ID: 7326167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia.
    Ellis FR; Clarke IM; Modgill M; Currie S; Harriman DG
    Br Med J; 1975 Aug; 3(5982):511-3. PubMed ID: 1164612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microcalorimetric studies in malignant hyperpyrexia susceptible individuals.
    Ranklev E; Monti M; Fletcher R
    Br J Anaesth; 1985 Oct; 57(10):991-3. PubMed ID: 4041326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperpyrexia.
    Ellis FR
    Anaesthesia; 1973 May; 28(3):245-52. PubMed ID: 4713948
    [No Abstract]   [Full Text] [Related]  

  • 11. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
    Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro diagnosis of malignant hyperpyrexia syndrome].
    Eldar I; Goldberg G; Glauber V; Perel A
    Harefuah; 1991 Dec; 121(12):499-502. PubMed ID: 1794753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the understanding of anaesthetic-induced malignant hyperpyrexia.
    Bull AB; Harrison GG
    Acta Anaesthesiol Belg; 1973 May; 24(2):97-108. PubMed ID: 4717678
    [No Abstract]   [Full Text] [Related]  

  • 14. Masseter muscle rigidity and malignant hyperthermia susceptibility.
    Rosenberg H; Fletcher JE
    Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive tests for malignant hyperpyrexia.
    Isaacs H; Heffron JJ; Badenhorst M
    Br J Anaesth; 1975 Oct; 47(10):1075-80. PubMed ID: 128373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of susceptibility to malignant hyperthermia in children].
    Krivosic-Horber R; Adnet P; Krivosic I; Reyford H
    Arch Fr Pediatr; 1990; 47(6):421-4. PubMed ID: 2403268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for malignant hyperpyrexia.
    Nelson TE; Austin KL; Denborough MA
    Br J Anaesth; 1977 Feb; 49(2):169-72. PubMed ID: 836748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant hyperpyrexia myopathy.
    Harriman DG; Sumner DW; Ellis FR
    Q J Med; 1973 Oct; 42(168):639-64. PubMed ID: 4802524
    [No Abstract]   [Full Text] [Related]  

  • 19. Site of the muscle cell abnormality in swine susceptible to malignant hyperpyrexia.
    Okumura F; Crocker BD; Denborough MA
    Br J Anaesth; 1980 Apr; 52(4):377-83. PubMed ID: 7378237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility?
    Flewellen EH; Nelson TE
    Anesth Analg; 1984 Jul; 63(7):693-7. PubMed ID: 6731899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.